Asset Details
Do you wish to reserve the book?
Analysis and interpretation of inflammatory fluid markers in Alzheimer’s disease: a roadmap for standardization
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Analysis and interpretation of inflammatory fluid markers in Alzheimer’s disease: a roadmap for standardization
Do you wish to request the book?
Analysis and interpretation of inflammatory fluid markers in Alzheimer’s disease: a roadmap for standardization
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Analysis and interpretation of inflammatory fluid markers in Alzheimer’s disease: a roadmap for standardization
2025
Overview
Growing interest in the role of the immune response in Alzheimer’s Disease and related dementias (ADRD) has led to widespread use of fluid inflammatory markers in research studies. To standardize the use and interpretation of inflammatory markers in AD research, we build upon prior guidelines to develop consensus statements and recommendations to advance application and interpretation of these markers. In this roadmap paper, we propose a glossary of terms related to the immune response in the context of biomarker discovery/validation, discuss current conceptualizations of inflammatory markers in research, and recommend best practices to address key knowledge gaps. We also provide consensus principles to summarize primary conceptual, methodological, and interpretative issues facing the field: (1) a single inflammatory marker is likely insufficient to describe an entire biological cascade, and multiple markers with similar or distinct functions should be simultaneously measured in a panel; (2) association studies in humans are insufficient to infer causal relationships or mechanisms; (3) neuroinflammation displays time-dependent and disease context-dependent patterns; (4) neuroinflammatory mechanisms should not be inferred based solely on blood inflammatory marker changes; and (5) standardized reporting of CSF inflammatory marker assay validation and performance will improve incorporation of inflammatory markers into the biological AD criteria.
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
Alzheimer Disease - cerebrospinal fluid
/ Alzheimer Disease - diagnosis
/ Alzheimer Disease - immunology
/ Biomarkers - cerebrospinal fluid
/ Biomedical and Life Sciences
/ Cerebrospinal fluid proteins
/ Humans
/ Immune
/ Inflammation - cerebrospinal fluid
/ Inflammation Mediators - cerebrospinal fluid
/ Review
